


**Amendments to the Claims:**

**This listing of claims will replace all prior versions of claims in the application.**

***Listing Of Claims:***

1. (Original) A compound of the formula,



wherein

R<sup>1</sup> is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;


R<sup>2</sup> is hydrogen or methyl;

**R<sup>3</sup> is hydrogen or hydroxy;**

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound according to Claim 1, wherein R<sup>1</sup> is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[(2R)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, or (L)-ornityl-(D)-ornitylamino.

3. (Original) The compound according to Claim 1, wherein R<sup>2</sup> and R<sup>3</sup> are hydrogen.
4. (Original) The compound according to Claim 1, wherein R<sup>1</sup> is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, and R<sup>2</sup> and R<sup>3</sup> are hydrogen.
5. (Original) The compound according to Claim 1, wherein R<sup>1</sup> is (L)-ornityl-(D)-ornitylamino, and R<sup>2</sup> and R<sup>3</sup> are hydrogen.
6. (Original)The compound according to Claim 1, wherein R<sup>1</sup> is N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R<sup>2</sup> and R<sup>3</sup> are hydrogen.
7. (Original)The compound according to Claim 1, wherein R<sup>1</sup> is N-(3-aminopropyl)-N-[(2R)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R<sup>2</sup> and R<sup>3</sup> are hydrogen.
8. (Original)The compound according to Claim 1, wherein R<sup>1</sup> is N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, and R<sup>2</sup> and R<sup>3</sup> are hydrogen.
9. (Original)The compound according to any of Claims 1 to 3, wherein R<sup>1</sup> is N-(2-aminoethyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R<sup>2</sup> and R<sup>3</sup> are hydrogen.
10. (Original) The compound according to Claim 1 wherein R<sup>2</sup> is methyl and R<sup>3</sup> is hydrogen.
11. (Original) The compound according to Claim 1 wherein R<sup>2</sup> is hydrogen and R<sup>3</sup> is hydroxyl.
12. (Original)A pharmaceutical composition comprising a mixture of a pharmaceutically acceptable carrier and an effective amount of a compound of the formula



wherein

R<sup>1</sup> is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;


R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen or hydroxy;

or a pharmaceutically acceptable salt thereof.

13. Canceled.

14. (Newly Presented) A method for the prophylactic or therapeutic treatment of mycoses which comprises administering to a human being or an animal an effective amount of the compound of the formula



wherein

R<sup>1</sup> is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen or hydroxy;

or a pharmaceutically acceptable salt thereof, thereby producing antifungal activity.